Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.

ABSTRACT: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment failure. To increase the efficacy of conventional chemotherapy, essential survival pathways should be targeted concomitantly. Here, we performed a loss-of-function siRNA screen of the human kinome in SaOS-2 cells to identify critical survival kinases after doxorubicin treatment. Gene silencing of JNK-interacting-protein-1 (JIP1) elicited the most potent sensitisation to doxorubicin. This candidate was further explored as potential target for chemosensitisation in OS. A panel of OS cell lines an

SUBMITTER: Posthumadeboer J 

PROVIDER: S-EPMC3717953 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature